Open access · CC-BY
via OpenAlex
Direct fibroblast reprogramming: an emerging strategy for treating organic fibrosis
Haohui Lin, Xia Wang, Manhon Chung, Sa Cai, Yu Pan
Journal of Translational Medicine · 2025 · ▲ 13 citations
Epigenetic alterations
Cellular senescence
Altered intercellular communication
Chronic inflammation
Gene therapy
Partial reprogramming (OSK)
Cell culture / in vitro
Review
Abstract
Direct reprogramming has garnered considerable attention due to its capacity to directly convert differentiated cells into desired cells. Fibroblasts are frequently employed in reprogramming studies due to their abundance and accessibility. However, they are also the key drivers in the progression of fibrosis, a pathological condition characterized by excessive extracellular matrix deposition and tissue scarring. Furthermore, the initial stage of reprogramming typically involves deactivating fibrotic pathways. Hence, direct reprogramming offers a valuable method to regenerate target cells for tissue repair while simultaneously reducing fibrotic tendencies. Understanding the link between reprogramming and fibrosis could help develop effective strategies to treat damaged tissue with a potential risk of fibrosis. This review summarizes the advances in direct reprogramming and reveals their anti-fibrosis effects in various organs such as the heart, liver, and skin. Furthermore, we dissect the mechanisms of reprogramming influenced by fibrotic molecules including TGF-β signaling, mechanical signaling, inflammation signaling, epigenetic modifiers, and metabolic regulators. Innovative methods for fibroblast reprogramming like small molecules, CRISPRa, modified mRNA, and the challenges of cellular heterogeneity and senescence(definition) faced by in vivo direct reprogramming, are also discussed.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1186/s12967-024-06060-3
- Canonical
- link ↗
- Fetched
- 2026-11-12 MST
Cite this
APA
Lin, H., Wang, X., Chung, M., Cai, S., & Pan, Y. (2025). Direct fibroblast reprogramming: an emerging strategy for treating organic fibrosis. <em>Journal of Translational Medicine</em>. https://doi.org/10.1186/s12967-024-06060-3
Vancouver
Lin H, Wang X, Chung M, Cai S, Pan Y. Direct fibroblast reprogramming: an emerging strategy for treating organic fibrosis. Journal of Translational Medicine. 2025. doi:10.1186/s12967-024-06060-3.
BibTeX
@article{haohui2025Direct,
title = {Direct fibroblast reprogramming: an emerging strategy for treating organic fibrosis},
author = {Haohui Lin and Xia Wang and Manhon Chung and Sa Cai and Yu Pan},
journal = {Journal of Translational Medicine},
year = {2025},
doi = {10.1186/s12967-024-06060-3},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
European Journal of Cell Biology 2022
Open access · CC-BY
Tackling the effects of extracellular vesicles in fibrosis
SHAREOK (University of Oklahoma; Oklahoma State University; Central Oklahoma University) 2023
Preprint
Determine the role of senescent cells in the Rostral Ventrolateral Medulla (RVLM) in mediating neuroinflammation and sympathoexcitation in obesity
Frontiers in Pharmacology 2025
Open access · CC-BY
Recent advances in dermal fibroblast senescence and skin aging: unraveling mechanisms and pioneering therapeutic strategies
HAL 2023
Preprint · OA
Implication of stress-induced Wip1 phosphatase in regulation of pluripotency and differentiation of stem cells
Aging Cell 2024
Open access · CC-BY
Clinical validation of C 12 FDG as a marker associated with senescence and osteoarthritic phenotypes
bioRxiv (Cold Spring Harbor Laboratory) 2022
Preprint · CC-BY